a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window There was a ...

Certain Medicare plans typically cover at least part of the cost of inhalers for COPD. There are also several ways to further save on costs.

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.

Tiotropium and aclidinium are currently available for prescription. Tiotropium is a once-daily inhaled ultra-LAMA for COPD that works through prolonged blockade of the M 3 muscarinic receptor.

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium ... to relieve symptoms in adults with COPD. Bevespi, which is taken twice daily, is part of a new generation of medicines that ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Flare-ups in chronic obstructive pulmonary disease, the UK’s fourth leading cause of death, can be reduced by 20% by a combined triple inhaler, according to the results of a trial of more than 2,000 ...

Inhalers may be prescribed to people who have a variety of health conditions both chronic and acute, including asthma, chronic obstructive pulmonary ... doing this daily or after a few usages ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...